FDA vet — and Woodcock nemesis — John Jenkins is stepping over to a new role as a board member at Corbus Pharma
After making headlines for his part in the FDA’s painful rupture over Sarepta’s Duchenne approval, news of John Jenkins has been rather slow. But now, the former head of the agency’s Office of New Drugs is stepping out to join the board of a small company just outside Boston.
Jenkins — who spent about 15 years working as the director of OND, overseeing the review of thousands of drug applications — is quite the catch for Corbus Pharmaceuticals. With his extensive regulatory background, it makes sense for companies to be seeking his insight on their boards. But Corbus is the first company board Jenkins agreed to sit on since leaving the FDA in 2017.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.